Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 3/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | CTSH | P09668 | 1/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.58 |
| ▸ | PTH1R | Q03431 | 8/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | MC5R | P33032 | 1/20 | 0.53 |
| ▸ | MC3R | P41968 | 1/20 | 0.53 |
| ▸ | MC1R | Q01726 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rinnipwseamm SCHEMBL30420540 | 0.95 | CXCR4 (0.58) | KEAP1CTSLCTSSCTSKCTSH | |
| SCHEMBL31694492 | 0.88 | KEAP1 (0.70) | KEAP1CXCR4PTH1RCXCL8 | |
| SCHEMBL31247476 | 0.86 | CAPN1 (0.54) | KEAP1CTSLCTSSCTSKCTSH | |
| SCHEMBL30512624 | 0.85 | CXCR4 (0.58) | KEAP1CTSLCTSSCTSKCTSH | |
| SCHEMBL30887976 | 0.85 | KEAP1 (0.69) | KEAP1CTSLCTSSCTSKCTSH | |
| SCHEMBL29415999 | 0.84 | NPY1R (0.59) | KEAP1CXCR4PTH1RCXCL8 | |
| SCHEMBL15483244 | 0.84 | KEAP1 (0.54) | KEAP1CTSLCTSSCTSKCTSH | |
| SCHEMBL30343340 | 0.84 | C5AR1 (0.60) | KEAP1CXCR4MC4RMC5RMC3R | |
| SCHEMBL30258085 | 0.84 | CXCL8 (0.55) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL30780078 | 0.84 | KEAP1 (0.57) | KEAP1CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093046-B2 | CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions | Philadelphia Health and Education Corporation d/b/c Drexel University College of Medicine (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093046-B2 | CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions | Philadelphia Health and Education Corporation d/b/c Drexel University College of Medicine (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090233850-A1 | CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233850-A1 | CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233850-A1 | CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions | CD4, LGALS1, IL1RN | KEAP1 3664/4885CTSL 1130/4885CTSS 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.